Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK.
about
Genetic polymorphisms of CYP2A13 and its relationship to nasopharyngeal carcinoma in the Cantonese populationCharacterization of CYP2A13*2, a variant cytochrome P450 allele previously found to be associated with decreased incidences of lung adenocarcinoma in smokersNicotine and 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone Binding and Access Channel in Human Cytochrome P450 2A6 and 2A13 EnzymesMiRNAs and miRNA Polymorphisms Modify Drug ResponseStructural features of cytochromes P450 and ligands that affect drug metabolism as revealed by X-ray crystallography and NMR.Pathway-BasedFeature Selection Algorithm for Cancer Microarray Data.Association of CYP2A6 activity with lung cancer incidence in smokers: The multiethnic cohort studyDesign, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data.Mechanisms of differential expression of the CYP2A13 7520C and 7520G alleles in human lung: allelic expression analysis for CYP2A13 heterogeneous nuclear RNA, and evidence for the involvement of multiple cis-regulatory single nucleotide polymorphismConversion events in gene clustersSingle nucleotide polymorphisms of 8 inflammation-related genes and their associations with smoking-related cancers.Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.Identification of cytochrome P450 enzymes critical for lung tumorigenesis by the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK): insights from a novel Cyp2abfgs-null mouseUGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers.Interactive effect of smoking and NQO1 haplotypes on lung cancer risk.A Cyp2a polymorphism predicts susceptibility to NNK-induced lung tumorigenesis in mice.Spectral modification and catalytic inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2A6, and 2A13 by four chemopreventive organoselenium compoundsSuppression of pulmonary CYP2A13 expression by carcinogen-induced lung tumorigenesis in a CYP2A13-humanized mouse model.Genetic variability in the metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL).Role of CYP2A5 in the bioactivation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in mice.Early manifestations of NNK-induced lung cancer: role of lung immunity in tumor susceptibility.Revealing mammalian evolutionary relationships by comparative analysis of gene clustersHypothesis-based weight-of-evidence evaluation and risk assessment for naphthalene carcinogenesis.Pilot study of CYP2B6 genetic variation to explore the contribution of nitrosamine activation to lung carcinogenesis.Expression of cytochrome P450 2A13 in human non-small cell lung cancer and its clinical significance.Transcriptional suppression of CYP2A13 expression by lipopolysaccharide in cultured human lung cells and the lungs of a CYP2A13-humanized mouse model.Role of CYP2A13 in the bioactivation and lung tumorigenicity of the tobacco-specific lung procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone: in vivo studies using a CYP2A13-humanized mouse model.Exposure and Metabolic Activation Biomarkers of Carcinogenic Tobacco-Specific Nitrosamines.Genetic determinants of cytochrome P450 2A6 activity and biomarkers of tobacco smoke exposure in relation to risk of lung cancer development in the Shanghai cohort study.Key residues controlling binding of diverse ligands to human cytochrome P450 2A enzymes.Benzylmorpholine analogs as selective inhibitors of lung cytochrome P450 2A13 for the chemoprevention of lung cancer in tobacco users.Nicotine Component of Cigarette Smoke Extract (CSE) Decreases the Cytotoxicity of CSE in BEAS-2B Cells Stably Expressing Human Cytochrome P450 2A13.Inhibition of human cytochromes P450 2A6 and 2A13 by flavonoids, acetylenic thiophenes and sesquiterpene lactones from Pluchea indica and Vernonia cinerea.Association of genetic polymorphisms CYP2A6*2 rs1801272 and CYP2A6*9 rs28399433 with tobacco-induced lung Cancer: case-control study in an Egyptian population.[Interference of homologous sequences on the SNP study of CYP2A13 gene].Oxidation of 1-chloropyrene by human CYP1 family and CYP2A subfamily cytochrome P450 enzymes: catalytic roles of two CYP1B1 and five CYP2A13 allelic variants.[Research progress of lung cancer on single nuleotide polymorphism].A model of cigarette smoke induced COPD identifies Nrf2 signaling as an expedient target for intervention
P2860
Q24563968-0AD439E5-16DD-452E-952B-2BC8A130397AQ24648582-FC407F5E-2771-41B1-8FD6-2435B70EC189Q27681173-6FBB518B-BE2E-4BF2-AEEB-94629552F053Q28079075-96AAEB4B-B726-43DB-8CF2-BE780F96EF11Q30396630-4CBB0295-44AE-4935-98C6-A9D59C81986DQ33537191-BB45E31E-A9B7-42AE-9E3F-3C4198FA92D5Q33728649-CECF8A04-5FBF-4018-968B-A2F9CD6DACF9Q33803436-D9E993F1-CCCB-4819-A8FA-496E09952AF0Q33872242-E1F9F4CA-52E3-44E9-86A3-7892F7E0A3F2Q33974268-D51AF754-7B5D-4F6D-8992-F0D3474852BBQ34101144-3F1299E1-AD1F-419C-B13C-F9981CC1348DQ34204238-2DBB4AA0-4625-421A-A127-C9938FFD70FFQ34434931-54CDAE91-8AD5-4B56-A1E6-9E9DEB9C3194Q34964392-3BCF1075-B680-43C5-8C6D-CF57AD8B28EEQ35089285-131F15DF-ACCE-4265-880E-52EBDA680D27Q35144532-6FFCA1B1-0B41-437F-9B0B-F65D217FF3D5Q35165381-6CA2AAD0-470B-4CF2-B106-380F97B962C5Q35531753-39782A98-6E44-499B-BBA5-A2C55FE290C9Q35638655-0CB0F425-5CA2-47D7-97E8-7A01D533AF2EQ35847688-F858798F-B561-4E94-8747-2794ABE405B3Q35855247-9E246ED8-8BA2-4400-A40E-E3479588C6AEQ35930303-C3D5E061-F11C-4304-A400-29BC357B21D0Q36518971-1E7A5758-B6F7-4704-8955-C2BF0D6CFD7AQ36820603-6732BBE3-2EFB-4ADC-BE5F-A81269FD06DFQ36878107-3D33C881-FD48-46B4-BCFC-3237E2EF0E79Q37253522-18A1EFCD-0C0A-4EEF-A140-36DBCF4FCA0CQ37412014-2AE3850F-0FD3-4B51-926F-E3136BD0A6B2Q37499926-175F812C-76DB-422F-A662-6332CE4AC826Q41054488-E4DBE128-AE8E-4B06-A955-7CA64482A27FQ42132207-9C1B0D98-D4AE-43B6-9DE1-6FCEE089F209Q42970314-C6454651-82E3-420E-A056-F93777A1E9A0Q45722657-13A5D6DF-D13F-4F85-AE0A-3F2CC8F4F6C3Q47735887-4FE98018-B3F3-4E55-A748-F51F9B85EB48Q53686438-E56ECEB2-9CD1-40B0-9B24-C0CEDEC1DA07Q54417586-698E1A68-2C27-4A57-B9E0-9C9587768E2FQ55004948-8A79249F-E18F-4C06-96C7-84C83236A56EQ55464618-8A31D2F0-0C3B-4E62-9889-F67FB1395C73Q58700499-46678C1A-8FEE-4A92-941A-D4CD707462BF
P2860
Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Substantial reduction in risk ...... bacco-specific carcinogen NNK.
@ast
Substantial reduction in risk ...... bacco-specific carcinogen NNK.
@en
Substantial reduction in risk ...... bacco-specific carcinogen NNK.
@nl
type
label
Substantial reduction in risk ...... bacco-specific carcinogen NNK.
@ast
Substantial reduction in risk ...... bacco-specific carcinogen NNK.
@en
Substantial reduction in risk ...... bacco-specific carcinogen NNK.
@nl
prefLabel
Substantial reduction in risk ...... bacco-specific carcinogen NNK.
@ast
Substantial reduction in risk ...... bacco-specific carcinogen NNK.
@en
Substantial reduction in risk ...... bacco-specific carcinogen NNK.
@nl
P2093
P1433
P1476
Substantial reduction in risk ...... obacco-specific carcinogen NNK
@en
P2093
Bingtao Hao
Dongxin Lin
Gangqiao Zhou
Haijian Wang
Xiaoping Miao
P304
P407
P577
2003-11-01T00:00:00Z